Solved Case Analysis: Genmor Pharmaceuticals Acquisition of Vascorex Corporation by Robert F. Bruner, Paul J. Simko, Mary Margaret Frank, David Martin, Marc Goldstein

0.00$

Get the Best Analysis to this Case Study written by MBA/CFA writers.

**Solution would be delivered to your registered email address within next 4 days. If you want the solution any earlier drop an email at assignment@writerkingdom.com.  Click Here to see how it works

Compare

Description

This case asks students to identify and evaluate the merits of two factors that have led a buy-side analyst to conclude that an acquiring company is a high-risk investment: (1) the company’s allocation of acquisition proceeds and (2) the quality of the target’s intellectual-property (IP) portfolio. The acquirer’s allocation of the acquisition cost of the target is quite different from that of one of the company’s previous deals. Careful interpretation of each line item for both acquisitions yields insights into the value management seeks with the acquisition. An IP-quality report supplied by an independent IP consulting firm likewise raises a number of issues students should identify. The primary objectives of the case are to (1) introduce IP-quality concepts as they relate to a firm’s patent portfolio, (2) understand the accounting basis for firms’ purchase-price allocations in IP-intensive acquisitions, and (3) compare and contrast the risk implications of acquisitions of in-process portfolios of drug candidates with established products.

Publishing Authority:

Darden Business Publishing – University of Virginia

Reviews

There are no reviews yet.

Be the first to review “Solved Case Analysis: Genmor Pharmaceuticals Acquisition of Vascorex Corporation by Robert F. Bruner, Paul J. Simko, Mary Margaret Frank, David Martin, Marc Goldstein”

Your email address will not be published. Required fields are marked *